Search Results - "SHUM, E"

A Upf3b-mutant mouse model with behavioral and neurogenesis defects by Huang, L, Shum, E Y, Jones, S H, Lou, C-H, Chousal, J, Kim, H, Roberts, A J, Jolly, L A, Espinoza, J L, Skarbrevik, D M, Phan, M H, Cook-Andersen, H, Swerdlow, N R, Gecz, J, Wilkinson, M F

“…Nonsense-mediated RNA decay (NMD) is a highly conserved and selective RNA degradation pathway that acts on RNAs terminating their reading frames in specific…”
Get full text

Sixteen years of social and ecological dynamics reveal challenges and opportunities for adaptive management in sustaining the commons by Cinner, J. E., Lau, J. D., Bauman, A. G., Feary, D. A., Januchowski-Hartley, F. A., Rojas, C. A., Barnes, M. L., Bergseth, B. J., Shum, E., Lahari, R., Ben, J., Graham, N. A. J.

“…Efforts to confront the challenges of environmental change and uncertainty include attempts to adaptively manage social–ecological systems. However, critical…”
Get full text

Emerging treatment using tubulin inhibitors in advanced non-small cell lung cancer by Hardin, C, Shum, E, Singh, A P, Perez-Soler, R, Cheng, H

“…Tubulin inhibitors including taxanes and vinca alkaloids are important components of chemotherapy regimens used in advanced non-small cell lung cancer (NSCLC)…”
Get more information

Adipose tissue estimation of foraging and nesting green turtles Chelonia mydas using bioelectrical impedance analysis by Kophamel, S, Ward, LC, Mendez, D, Ariel, E, Bell, I, Shum, E, Munns, SL

“…Adipose tissue is the main energy store in sea turtles and fluctuates in response to dietary conditions and external stressors. Monitoring programmes commonly…”
Get full text

Intracranial activity of ensartinib in patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) by Wakelee, H., Reckamp, K.L., Leal, T.A., Patel, S.P., Blumenschein, G., Shum, E., Nieva, J., Oxnard, G., Sanborn, R.E., Waqar, S., Zeman, K., Dukart, G., Harrow, K., Liang, C., Holzhausen, A., Horn, L.

Get full text

Development of horticultural therapy in Hong Kong by Fung, C.Y.Y, Shum, E.T.Y

“…The profession of horticultural therapy (HT) began in Hong Kong in 2005 with the establishment of the Hong Kong Horticultural Therapy Centre (HKHTC) as the…”
Get full text

Formation of Neu/ErbB2-induced mammary tumors is unaffected by loss of ErbB4 by JACKSON-FISHER, A. J, BELLINGER, G, SHUM, E, DUONG, J. K, PERKINS, A. S, GASSMANN, M, MULLER, W, KENT LLOYD, K. C, STERN, D. F

“…The four members of the ErbB family of receptor tyrosine kinases are involved in development and tumorigenesis of the mammary gland. Whereas the epidermal…”
Get full text

485P LDCT lung cancer screening of never-smokers meta-analysis subgroup analysis: Adenocarcinoma is the highly predictive histology identified in never-smokers by Triphuridet, N., Nagasaka, M., Shum, E., Ou, S-H.I.

Get full text

The Selective Personalized Radioimmunotherapy for Locally Advanced NSCLC Trial (SPRINT): Patient-Reported Outcomes by Ohri, N., Jolly, S., Cooper, B., Kabarriti, R., Bodner, W.R., Guha, C., Viswanathan, S., Shum, E., Sabari, J.K., Cheng, H., Gucalp, R., Castellucci, E., Qin, A., Gadgeel, S.M., Halmos, B.

“…Initial reports from the Selective Personalized Radioimmunotherapy for Locally Advanced NSCLC Trial (SPRINT) indicated that patients with high PD-L1 expression…”
Get full text

LBA71 A multi-centre open-label randomized phase II study of osimertinib with and without ramucirumab in TKI-naïve EGFR-mutant metastatic NSCLC (RAMOSE trial interim analysis) by Le, X., Patel, J., Shum, E., Sanborn, R.E., Baik, C.S., Shu, C.A., Kim, C., Fidler, M.D., Hall, R., Hanna, N., Mohindra, N., Sabari, J.K., Heeke, S., Hernandez, M., Gray, J.E., Heymach, J.V., Saltos, A.

Get full text

The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial (SPRINT) by Ohri, N., Jolly, S., Cooper, B.T., Kabarriti, R., III, W. R. Bodner, Klein, J., Viswanathan, S., Kaufman, R., Shum, E., Sabari, J.K., Cheng, H., Gucalp, R., Castellucci, E., Qin, A., Gadgeel, S.M., Halmos, B.

Get full text

1018P Phase I/II trial of rigosertib and nivolumab for KRAS mutated non-small cell lung cancer (NSCLC) patients by Veluswamy, R., Bhalla, S., Samstein, R., Marron, T., Gomez, J.E., Doroshow, D.B., Sabari, J., Shum, E., Saxena, A., Namakydoust, A., Chachoua, A., Wisnivesky, J., Mandeli, J., Bhardwaj, N., Hirsch, F.R., Merad, M., Reddy, E.

Get full text

36MO Safety, tolerability and preliminary efficacy of poziotinib with twice daily strategy in EGFR/HER2 Exon 20 mutant non-small cell lung cancer by Sacher, A., Le, X., Cornelissen, R., Shum, E., Suga, J., Socinski, M., Molina, J.R., Haura, E., Clarke, J., Bhat, G., Lebel, F., Garassino, M.C.

Get full text

518MO TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs) by Kitazono, S., Paz-Ares, L., Ahn, M-J., Lisberg, A.E., Cho, B.C., Blumenschein, G., Shum, E., Pons-Tostivint, E., Goto, Y., Yoh, K., Heist, R., Baas, P., Planchard, D., Pérol, M., Felip, E., Su, W-C., Zebger-Gong, H., Lan, L., Liu, C., Sands, J.

Get full text

1314MO TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs) by Paz-Ares, L., Ahn, M-J., Lisberg, A.E., Kitazono, S., Cho, B.C., Blumenschein, G., Shum, E., Pons-Tostivint, E., Goto, Y., Yoh, K., Heist, R., Baas, P., Planchard, D., Pérol, M., Felip, E., Su, W-C., Zebger-Gong, H., Lan, L., Liu, C., Sands, J.

Get full text

Hepatitis B Seroprevalence Study 1999 by James, L, Fong, C W, Foong, B H, Wee, M K, Chow, A, Shum, E, Chew, S K

“…Hepatitis B is a disease of public health importance in Singapore. A study was conducted in 1999 to estimate the overall and gender-, age- and ethnic-specific…”
Get more information

BLU-945 Monotherapy and Combination With Osimertinib in Previously Treated Patients With Advanced EGFR-Mutant (EGFRm) NSCLC in Phase 1/2 SYMPHONY Study by Elamin, Y., Nagasaka, M., Shum, E., Bazhenova, L., Rotow, J., Spigel, D.R., Tan, D.S.W., Zalutskaya, A., Albayya, F., Reckamp, K.L.

Get full text

Virtual multidisciplinary stroke care clinic for community-dwelling stroke survivors: a randomised controlled trial (abridged secondary publication) by Chau, J P C, Lo, S H S, Lau, A Y L, Lee, V W Y, Choi, K C, Shum, E W C, Hung, S S, Mok, V C T, Siow, E K C, Ching, J Y L, Lam, S K Y

Get full text

1496PIntracranial activity of ensartinib in patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) by Wakelee, H, Reckamp, K L, Leal, T A, Patel, S P, Blumenschein, G, Shum, E, Nieva, J, Oxnard, G, Sanborn, R E, Waqar, S, Zeman, K, Dukart, G, Harrow, K, Liang, C, Holzhausen, A, Horn, L

Get full text

Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey by Ou, Sai-Hong Ignatius, Le, Xiuning, Nagasaka, Misako, Reungwetwattana, Thanyanan, Ahn, Myung-Ju, Lim, Darren W T, Santos, Edgardo S, Shum, Elaine, Lau, Sally C M, Lee, Jii Bum, Calles, Antonio, Wu, Fengying, Lopes, Gilberto, Sriuranpong, Virote, Tanizaki, Junko, Horinouchi, Hidehito, Garassino, Marina C, Popat, Sanjay, Besse, Benjamin, Rosell, Rafael, Soo, Ross A

“…The year 2024 is the 20 anniversary of the discovery of activating epidermal growth factor receptor ( ) mutations in non-small cell lung cancer (NSCLC). Since…”
Get full text